Page 368 - Read Online

Gururangan et al. Neuroimmunol Neuroinflammation 2018;5:45 I http://dx.doi.org/10.20517/2347-8659.2018.44 Page 13 of 15

34. Mehling M, Simon P, Mittelbronn M, Meyermann R, Ferrone S, et al. WHO grade associated downregulation of MHC class I antigen-
processing machinery components in human astrocytomas: does it reflect a potential immune escape mechanism? Acta Neuropathol
2007;114:111-9.
35. Vermeulen JF, Van Hecke W, Adriaansen EJM, Jansen MK, Bouma RG, et al. Prognostic relevance of tumor-infiltrating lymphocytes
and immune checkpoints in pediatric medulloblastoma. Oncoimmunology 2017;7:e1398877.
36. Smith C, Santi M, Rushing EJ, Cornelison R, MacDonald TJ, et al. Characterization of signaling function and expression of HLA class I
molecules in medulloblastoma. J Neurooncol 2011;103:197-206.
37. Raffaghello L, Nozza P, Morandi F, Camoriano M, Wang X, et al. Expression and functional analysis of human leukocyte antigen class
I antigen-processing machinery in medulloblastoma. Cancer Res 2007;67:5471-8.
38. Thompson YY, Ramaswamy V, Diamandis P, Daniels C, Taylor MD. Posterior fossa ependymoma: current insights. Childs Nerv Syst
2015;31:1699-706.
39. Mack SC, Pajtler KW, Chavez L, Okonechnikov K, Bertrand KC, et al. Therapeutic targeting of ependymoma as informed by oncogenic
enhancer profiling. Nature 2018;553:101-5.
40. Griesinger AM, Birks DK, Donson AM, Amani V, Hoffman LM, et al. Characterization of distinct immunophenotypes across pediatric
brain tumor types. J Immunol 2013;191:4880-8.
41. Lin GL, Nagaraja S, Filbin MG, Suvà ML, Vogel H, et al. Non-inflammatory tumor microenvironment of diffuse intrinsic pontine
glioma. Acta Neuropathol Commun 2018;6:51.
42. McNamara MA, Nair SK, Holl EK. RNA-based vaccines in cancer immunotherapy. J Immunol Res 2015;2015:794528.
43. Holl EK, Brown MC, Boczkowski D, McNamara MA, George DJ, et al. Recombinant oncolytic poliovirus, PVSRIPO, has potent
cytotoxic and innate inflammatory effects, mediating therapy in human breast and prostate cancer xenograft models. Oncotarget
2016;7:79828-41.
44. Benitez-Ribas D, Cabezón R, Flórez-Grau G, Molero MC, Puerta P, et al. Immune response generated with the administration of
autologous dendritic cells pulsed with an allogenic tumoral cell-lines lysate in patients with newly diagnosed diffuse intrinsic pontine
glioma. Front Oncol 2018;8:127.
45. Mitchell D, Archer G, Bigner D, Friedman A, Friedman H, et al. RNA-loaded dendritic cells targeting cytomegalovirus in patients with
malignant glioma. Neuro Oncol 2007;9:509.
46. Mitchell DA, Batich KA, Gunn MD, Huang MN, Sanchez-Perez L, et al. Tetanus toxoid and CCL3 improve dendritic cell vaccines in
mice and glioblastoma patients. Nature 2015;519:366-9.
47. Hu Z, Ott PA, Wu CJ. Towards personalized, tumour-specific, therapeutic vaccines for cancer. Nat Rev Immunol 2018;18:168-82.
48. Sampson JH, Aldape KD, Archer GE, Coan A, Desjardins A, et al. Greater chemotherapy-induced lymphopenia enhances tumor-specific
immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro Oncol 2011;13:324-33.
49. Gilboa E. The makings of a tumor rejection antigen. Immunity 1999;11:263-70.
50. Boczkowski D, Nair SK, Nam JH, Lyerly HK, Gilboa E. Induction of tumor immunity and cytotoxic T lymphocyte responses using
dendritic cells transfected with messenger RNA amplified from tumor cells. Cancer Research 2000;60:1028-34.
51. Heiser A, Maurice MA, Yancey DR, Wu NZ, Dahm P, et al. Induction of polyclonal prostate cancer-specific CTL using dendritic cells
transfected with amplified tumor RNA. J Immunol 2001;166:2953-60.
52. Nair SK, Morse M, Boczkowski D, Cumming RI, Vasovic L, et al. Induction of tumor-specific cytotoxic T lymphocytes in cancer
patients by autologous tumor RNA-transfected dendritic cells. Ann Surg 2002;235:540-9.
53. Learn CA, Grossi PM, Schmittling RJ, Xie W, Mitchell DA, et al. Genetic analysis of intracranial tumors in a murine model of glioma
demonstrate a shift in gene expression in response to host immunity. J Neuroimmunol 2007;182:63-72.
54. Dannull J, Su Z, Rizzieri D, Yang BK, Coleman D, et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after
depletion of regulatory T cells. J Clin Invest 2005;115:3623-33.
55. Ashley DM, Faiola B, Nair S, Hale LP, Bigner DD, et al. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor
RNA induce antitumor immunity against central nervous system tumors. J Exp Med 1997;186:1177-82.
56. Bryant CE, Sutherland S, Kong B, Papadimitrious MS, Fromm PD, et al. Dendritic cells as cancer therapeutics. Semin Cell Dev Biol
2018; doi: 10.1016/j.semcdb.2018.02.015.
57. Verdijk P, Aarntzen EH, Lesterhuis WJ, Boullart AC, Kok E, et al. Limited amounts of dendritic cells migrate into the T-cell area of
lymph nodes but have high immune activating potential in melanoma patients. Clin Cancer Res 2009;15:2531-40.
58. Shi Y, Liu CH, Roberts AI, Das J, Xu G, et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF) and T-cell responses: what
we do and don’t know. Cell Res 2006;16:126-33.
59. Parmiani G, Castelli C, Pilla L, Santinami M, Colombo MP, et al. Opposite immune functions of GM-CSF administered as vaccine
adjuvant in cancer patients. Ann Oncol 2007;18:226-32.
60. Gupta R, Emens LA. GM-CSF-secreting vaccines for solid tumors: moving forward. Discov Med 2010;10:52-60.
61. Mitchell DA, Sayour EJ, Reap E, Schmittling R, DeLeon G, et al. Severe adverse immunologic reaction in a patient with glioblastoma
receiving autologous dendritic cell vaccines combined with GM-CSF and dose-intensified temozolomide. Cancer Immunol Res
2015;3:320-5.
62. Morgan DA, Ruscetti FW, Gallo R. Selective in vitro growth of T lymphocytes from normal human bone marrows. Science
1976;193:1007-8.
63. Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol
2012;12:269-81.
64. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, et al. Cancer regression and autoimmunity in patients after clonal
repopulation with antitumor lymphocytes. Science 2002;298:850-4.
65. Fecci PE, Sweeney AE, Grossi PM, Nair SK, Learn CA, et al. Systemic anti-CD25 monoclonal antibody administration safely enhances